DavisMP, FrandsenJL, WalshD, et al.: Mirtazapine for pruritus. J Pain Sympt Manag, 2003; 25:288–291.
2.
KhannaR, BoozalisE, BelzbergM, et al.: Mirtazapine for the treatment of chronic pruritus. Medicines, 2019; 6:E73.
3.
FawazB, ChamseddinBH, GriffinJR: Defining the role of mirtazapine in the treatment of refractory pruritus. J Dermatolog Treat, 2019:1–5.
4.
AkhanA, SubasiFD, BosnaG, et al.: Comparison of mirtazapine, gabapentin and ondansetron to prevent intrathecal morphine-induced pruritus. Northern Clin Istanb, 2016; 3:53–59.
5.
LeeJJ, GirouardSD, CarlbergVM, MostaghimiA: Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse. BMJ Support Palliat Care, 2016; 6:119–121.
6.
WinegardenJA, CarrDB, BradshawYS: Topical ketamine with other adjuvants: Underutilized for refractory cancer pain? A case series and suggested revision of the World Health Organization stepladder for cancer pain. J Palliat Med, 2020. [Epub ahead of print; DOI: 10.1089/jpm.2019.0618.]
7.
EastmanP, LeB: Corticosteroids as co-analgesics with opioids for cancer pain: A survey of Australian and New Zealand palliative care clinicians. Intern Med J, 2015; 45:1306–1310.
8.
PaulsenO, AassN, KaasaS, DaleO: Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Sympt Manag, 2013; 46:96–105.
9.
BrutcherRE, KuriharaC, BicketMC, et al.: Compounded topical pain creams to treat localized chronic pain: A randomized controlled trial. Ann Intern Med, 2019; 170:309–318.
10.
JonkmanK, van de DonkT, DahanA: Ketamine for cancer pain: What is the evidence?. Curr Opin Support Palliat Care, 2017; 11:88–92.
